Impact of mass drug administration of azithromycin for trachoma elimination on prevalence and azithromycin resistance of genital Mycoplasma genitalium infection.

ABSTRACT:

Background

Mass drug administration (MDA) of 20 mg/kg (maximum 1 g in adults) azithromycin for ocular Chlamydia trachomatis (CT) infection is a key component of the WHO trachoma elimination strategy. However, this dose may be suboptimal in Mycoplasma genitalium infection and may encourage emergence of antimicrobial resistance (AMR) to azithromycin.

Objectives

To determine the effect of MDA for trachoma elimination on M. genitalium prevalence, strain type and azithromycin resistance.

Methods

A secondary analysis of CT-negative vulvovaginal swabs from three outpatient antenatal clinics (Honiara, Solomon Islands) from patients recruited either pre-MDA, or 10 months post-MDA in two cross-sectional surveys was carried out. Swabs were tested for M. g

SUBMITTER: Harrison MA 

PROVIDER: S-EPMC6860407 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature